Literature DB >> 24257691

A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease.

Yi-Chun Chen1, Hon-Yi Lin2, Chung-Yi Li3, Moon-Sing Lee2, Yu-Chieh Su4.   

Abstract

The association of hepatitis C virus (HCV) infection with chronic kidney disease (CKD) remains widely debated. Here we quantify this association by analysis of data from the Taiwan National Health Insurance Research Database and ICD-9 codes to identify 9430 adults with newly diagnosed HCV (years 1999-2006) and randomly selected 37,720 matched non-HCV control individuals. The incidence rate and risk of incident CKD were evaluated through the end of 2010. The frequency of CKD was 1.66-fold higher in the HCV than the non-HCV cohort (5.46 compared with 3.43 per 1000 person-years), and the adjusted hazard ratio remained significant at 1.28 (95% confidence interval, 1.12-1.46). A multivariate analysis was used to determine the influence of HCV on CKD risk with regard to age, gender, follow-up duration, and comorbidities. The risk for CKD in HCV-infected individuals was higher with diabetes, hyperlipidemia, and cirrhosis (8.44; 3.70-19.23), followed by men<50 years (2.32; 1.49-3.61), all individuals<50 years (1.90; 1.33-2.73), men overall (1.44; 1.22-1.71), and individuals followed for ≥6 years (1.35; 1.06-1.71); all with considerable significance. Thus, HCV infection is associated with an increased risk of CKD. Hence, high-risk HCV-infected individuals should be aggressively monitored for development of CKD.

Entities:  

Mesh:

Year:  2013        PMID: 24257691     DOI: 10.1038/ki.2013.455

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  47 in total

1.  Association of Hepatitis C Virus Infection with Proteinuria and Glomerular Filtration Rate.

Authors:  Nargiza Kurbanova; Rehan Qayyum
Journal:  Clin Transl Sci       Date:  2015-08-14       Impact factor: 4.689

2.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

Review 3.  Hepatitis C and kidney disease: An overview and approach to management.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Hepatol       Date:  2015-01-27

4.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

5.  Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.

Authors:  Yuval A Patel; Andrew J Muir
Journal:  Curr Hepatol Rep       Date:  2016-11-05

Review 6.  Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease.

Authors:  Anita Kohli; Ali Alshati; Fawaz Georgie; Richard Manch; Robert G Gish
Journal:  Therap Adv Gastroenterol       Date:  2016-09-14       Impact factor: 4.409

Review 7.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Fabrizio Fabrizi; Simona Verdesca; Piergiorgio Messa; Paul Martin
Journal:  Dig Dis Sci       Date:  2015-07-21       Impact factor: 3.199

Review 8.  Hepatitis C Virus Infection in Chronic Kidney Disease.

Authors:  Marco Ladino; Fernando Pedraza; David Roth
Journal:  J Am Soc Nephrol       Date:  2016-04-19       Impact factor: 10.121

Review 9.  Hepatitis C Virus Infection in the Older Patient.

Authors:  Michael Reid; Jennifer C Price; Phyllis C Tien
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

10.  Association of Tinnitus and Other Cochlear Disorders With a History of Migraines.

Authors:  Juen-Haur Hwang; Shiang-Jiun Tsai; Tien-Chen Liu; Yi-Chun Chen; Jen-Tsung Lai
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.